TAVEGIL Solution for injection 2 mg/2 ml ampoules, 5X2 ml

Instructions for use for TAVEGIL Solution for injection 2 mg/2 ml ampoules, 5X2 ml

Instructions for use of the article Tavegil solution for injection 2 Mg/2 Ml ampoules. Tavegil solution for injection contains the active substance clemastine fumarate and is used for premedication, before the administration of radiological contrast media. It is also used for the short-term acute treatment of severe allergic diseases. Note that Tavegil solution for injection contains 6.5% alcohol by volume. The leaflet provides important information that you should read carefully. Keep the leaflet and ask your pharmacist if you have any questions. If your symptoms get worse or do not improve, consult a doctor. Tell your doctor or pharmacist if you notice any side effects or if this leaflet contains information that is not stated. The leaflet contains the following sections: - WAS IST TAVEGIL INJEKTIONSLÖSUNG UND WOFÜR WIRD SIE USED? - WAS MÜSSEN SIE VOR DER ANWENDUNG VON TAVEGIL INJEKTIONSLÖSUNG NOTE? - WIE IST TAVEGIL INJEKTIONSLÖSUNG HOW TO USE? - WELCHE NEBENWIRKUNGEN SIND POSSIBLE? - WIE IST TAVEGIL INJEKTIONSLÖSUNG HOW TO STORE? - WEITERE INFORMATIONEN You should take certain precautions when using Tavegil Solution for Injection, especially if you have certain medical conditions. Tell your doctor or pharmacist about other medicines you are taking as they may interact with each other. The use of Tavegil Solution for Injection during pregnancy and breast-feeding should be on the advice of a doctor. Tavegil solution for injection may impair the ability to react, especially in combination with alcohol. For more important information about specific ingredients, dosage, use, side effects, storage and manufacturer, see the package leaflet. Note that this information was last updated in July 2015. General information from our pharmacists: Our products are supplied in household quantities with a maximum of 15 packs per quarter. However, specific maximum quantities may be set for certain medicines to ensure drug safety. The information in this summary has been taken from the source indicated and does not contain repeated information. No tables, bold or h tags or colour tags have been used.